PKO Investment Management Joint Stock Co Has $1.94 Million Stock Holdings in Stryker Co. (NYSE:SYK)

PKO Investment Management Joint Stock Co lifted its stake in Stryker Co. (NYSE:SYK) by 73.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,200 shares of the medical technology company’s stock after acquiring an additional 2,200 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Stryker were worth $1,936,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $25,000. Capital A Wealth Management LLC bought a new stake in Stryker during the fourth quarter worth $26,000. Rakuten Securities Inc. lifted its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker in the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker during the 4th quarter worth about $33,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK opened at $377.05 on Tuesday. The firm has a market cap of $143.91 billion, a PE ratio of 48.59, a PEG ratio of 2.93 and a beta of 0.91. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $373.53 and its two-hundred day moving average price is $375.55. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the business posted $2.50 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is currently 45.41%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 5.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Evercore ISI reduced their target price on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Monday, May 5th. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.